Biotech stocks posted weekly declines in the week ended Oct. 23, pressured by the broader market decline amid mixed earnings reports and the impasse on fiscal stimulus.
After declining in the first three sessions of the week, the iShares Nasdaq Biotechnology Etf (NASDAQ: IBB) rebounded in the next two, thereby recouping some of the losses.
Biogen Inc’s (NASDAQ: BIIB) third-quarter report headlined the biopharma earnings news flow of the week. Although the initial reaction was positive due to the better-than-expected headline numbers, the stock came under selling pressure subsequently, as investors fretted over accelerating decline in Spinraza sales and the looming binary event for Alzheimer’s treatment candidate aducanumab.
On the coronavirus vaccine front, AstraZeneca plc (NASDAQ: AZN) experienced another scare as a trial participant was reported as dead in Brazil. The U.K. biopharma, however, was vindicated as reports later said the said participant was administered placebo and not the investigational vaccine.
Moderna Inc (NASDAQ: MRNA) completed enrollment in its Phase 3 COVE study, with the company now looking ahead to the interim readout.
Gilead Sciences, Inc.’s (NASDAQ: GILD) Veklury was accorded full FDA approval during the week.
Expectedly, Zosano Pharma Corp (NASDAQ: ZSAN) was handed down a complete response letter for the NDA for its migraine patch. The penny stock slumped about 40% at one point in time in the week before recovering some of the lost ground.
The week witnessed the Nasdaq debut of Foghorn Therapeutics, which raised $120 million in an initial public offering.
Here are the key catalysts for the unfolding week.
American Society of Nephrology, or ASN, Kidney Week 2020 Annual Meeting: Oct. 22-25
EORTC-NCI-AACR Annual, or ENA 2020, Symposium on Molecular Targets and Cancer Therapeutics: Oct. 24-25
ASTRO Annual Meeting 2020: Oct. 24-28
Macrophage-directed Therapies Summit: Oct 27-29
American Society of Human Genetics, or ASHG, Virtual Meeting 2020: Oct. 27-30
Cantor Fitzgerald “Key Considerations for Gene Therapy Manufacturing and Platforms” virtual panel: Oct. 28
B. Riley Securities Liver Disease Therapeutics Day: Oct. 29
European Academy Dermatology and Venereology, or EADV, Virtual 29th Congress: Oct. 29-31
The FDA is scheduled to rule on Kala Pharmaceuticals Inc’s (NASDAQ: KALA) NDA for Eysuvis, or loteprednol etabonate ophthalmic suspension, 0.25%, which is being evaluated for the short-term treatment of the signs and symptoms of dry eye disease. The PDUFA action date is Oct. 30.
By the same day, the agency is set to rule on Merck & Co., Inc.’s (NYSE: MRK) sBLA for Keytruda as a monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin’s lymphoma.
Related Link: Why This Bluebird Bio Analyst Sees Over 125% Upside Ahead
Applied Therapeutics Inc (NASDAQ: APLT) is due to present at the ASHG meeting animal model efficacy data and adult clinical data on the safety and biomarker efficacy of its investigational candidate for Galactosemia, AT-007. (Monday)
Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) has scheduled a webcast on Monday at 4:30 pm to provide investors with an update on Xywav oral solution, which was approved by the FDA in late July for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
Retrophin Inc (NASDAQ: RTRX) is scheduled to present at the ASN Kidney Week 2020 Reimagined, new data from a post-hoc analysis examining the proportion of patients with focal segmental glomerulosclerosis that achieved complete remission of proteinuria in the Phase 2 DUET Study of sparsentan. Sparsentan has been licensed from Ligand Pharmaceuticals Inc. (NASDAQ: LGND).
Galera Therapeutics Inc (NASDAQ: GRTX is due to present at the ASTRO annual meeting data from its Phase 1b/2a clinical trial of avasopasem manganese (GC4419) in combination with stereotactic body radiation therapy for locally advanced pancreatic cancer (Tuesday).
Concert Pharmaceuticals Inc (NASDAQ: CNCE) will present clinical data on CTP-543 for the treatment of alopecia areata as a late-breaker oral presentation at the 29th EADV Virtual Congress (Thursday).
Axovant Gene Therapies Ltd (NASDAQ: AXGT) is due to present at its virtual Parkinson’s disease R&D day individual patient-level data from Cohort 2 of the Phase 2 SUNRISE-PD study that is evaluating its AXO-Lenti-PD gene therapy for the treatment of Parkinson’s disease (Friday).
Dynavax Technologies Corporation’s (NASDAQ: DVAX) partner Medicago is scheduled to release safety and immunogenicity results from the Phase I clinical trial for its plant-derived COVID-19 vaccine candidate that uses Dynavax’ adjuvant CpG 1018.
Medpace Holdings Inc (NASDAQ: MEDP) (before the market open)
Laboratory Corp. of America Holdings (NYSE: LH) (before the market open)
Merck & Co., Inc. (NYSE: MRK) (before the market open)
Pfizer Inc. (NYSE: PFE) (before the market open)
NeoGenomics, Inc. (NASDAQ: NEO) (before the market open)
Masimo Corporation (NASDAQ: MASI) (after the close)
DexCom, Inc. (NASDAQ: DXCM) (after the close)
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) (after the close)
Omnicell, Inc. (NASDAQ: OMCL) (after the close)
Integra Lifesciences Holdings Corp (NASDAQ: IART) (before the market open)
United Therapeutics Corporation (NASDAQ: UTHR) (before the market open)
PPD Inc (NASDAQ: PPD) (before the market open)
Boston Scientific Corporation (NYSE: BSX) (before the market open)
Aethlon Medical, Inc. (NASDAQ: AEMD) (after the close)
Amgen, Inc. (NASDAQ: AMGN) (after the close)
Alimera Sciences Inc (NASDAQ: ALIM) (after the close)
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (after the close)
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) (after the close)
Globus Medical Inc (NYSE: GMED) (after the close)
Gilead Sciences, Inc. (NASDAQ: GILD) (after the close)
Merit Medical Systems, Inc. (NASDAQ: MMSI) (after the close)
Penumbra Inc (NYSE: PEN) (after the close)
Viking Therapeutics Inc (NASDAQ: VKTX) (after the close)
Evelo Biosciences Inc (NASDAQ: EVLO) (before the market open)
Baxter International Inc (NYSE: BAX) (before the market open)
Blueprint Medicines Corp (NASDAQ: BPMC) (before the market open)
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) (before the market open)
Agenus Inc (NASDAQ: AGEN) (before the market open)
ABIOMED, Inc. (NASDAQ: ABMD) (before the market open)
Pacira Biosciences Inc (NASDAQ: PCRX) (before the market open)
Protalix Biotherapeutics Inc (NYSE: PLX) (before the market open)
Insmed Incorporated (NASDAQ: INSM) (before the market open)
Moderna Inc (NASDAQ: MRNA) (before the market open)
Novocure Ltd (NASDAQ: NVCR) (before the market open)
Syneos Health Inc (NASDAQ: SYNH) (before the market open)
Xtant Medical Holdings Inc (NYSE: XTNT) (before the market open)
Constellation Pharmaceuticals Inc (NASDAQ: CNST) (before the market open)
Alkermes Plc (NASDAQ: ALKS) (before the market open)
AxoGen, Inc Common Stock (NASDAQ: AXGN) (after the close)
BioTelemetry Inc (NASDAQ: BEAT) (after the close)
PTC Therapeutics, Inc. (NASDAQ: PTCT) (after the close)
Illumina, Inc. (NASDAQ: ILMN) (after the close)
Natus Medical Inc (NASDAQ: NTUS) (after the close)
LeMaitre Vascular Inc (NASDAQ: LMAT) (after the close)
ResMed Inc. (NYSE: RMD) (after the close)
NuVasive, Inc. (NASDAQ: NUVA) (after the close)
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) (after the close)
Opko Health Inc. (NASDAQ: OPK) (after the close)
Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) (after the close)
Quidel Corporation (NASDAQ: QDEL) (after the close)
EXACT Sciences Corporation (NASDAQ: EXAS) (after the close)
Cerus Corporation (NASDAQ: CERS) (after the close)
CareDx Inc (NASDAQ: CDNA) (after the close)
Boulder, Colorado-based Biodesix, Inc., a data-driven diagnostic solutions company, has filed to offer 4.17 million shares in an initial public offering, or IPO, at an estimated price range of $17-$19. The company has applied for listing its shares on the Nasdaq under the ticker symbol BDSX.
Galecto, Inc., a Wilmington, Delaware-based clinical-stage biotech company developing therapeutics for fibrosis, is proposing to offer 5.67 million shares at an estimated price range of $14-$16. The company expects its shares to trade on the Nasdaq under the ticker symbol GLTO.
Atlanta, Georgia-based Inhibikase Therapeutics, Inc. has filed for offering 2.272 million shares of its common stock to be priced between $10 and $12 apiece. The shares are to be listed on the Nasdaq under the ticker symbol IKT. Inhibikase is a clinical stage pharmaceutical company developing therapeutics for Parkinson’s disease.
IPO Quiet Period Expiry
Pulmonx Corp (NASDAQ: LUNG)
Oncorus Inc (NASDAQ: ONCR)
Immunome Inc (NASDAQ: IMNM)
C4 Therapeutics Inc (NASDAQ: CCCC)
CDC’s Advisory Committee on Immunization Practices panel will meet Oct. 28-30, which is one of its customary three yearly meetings to review scientific data and vote on vaccine recommendations.
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.